LeMaitre Vascular Files 8-K on Financials
Ticker: LMAT · Form: 8-K · Filed: May 2, 2024 · CIK: 1158895
| Field | Detail |
|---|---|
| Company | Lemaitre Vascular Inc (LMAT) |
| Form Type | 8-K |
| Filed Date | May 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations
Related Tickers: LMAT
TL;DR
LeMaitre Vascular dropped an 8-K on financials, check it for the latest numbers.
AI Summary
On May 2, 2024, LeMaitre Vascular, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with no specific new financial figures or significant events detailed in the provided text.
Why It Matters
This filing provides an update on LeMaitre Vascular's financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- LeMaitre Vascular, Inc. (company) — Registrant
- 001-33092 (company) — Commission File Number
- 63 Second Avenue Burlington, MA 01803 (company) — Address of principal executive offices
- 781 - 221-2266 (company) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for LeMaitre Vascular, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 2, 2024.
What is LeMaitre Vascular, Inc.'s Commission File Number?
LeMaitre Vascular, Inc.'s Commission File Number is 001-33092.
Where are LeMaitre Vascular, Inc.'s principal executive offices located?
LeMaitre Vascular, Inc.'s principal executive offices are located at 63 Second Avenue, Burlington, MA 01803.
What is the telephone number for LeMaitre Vascular, Inc.?
The telephone number for LeMaitre Vascular, Inc. is 781-221-2266.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2024-05-02 16:13:26
Key Financial Figures
- $0.01 — nge on which registered Common stock , $0.01 par value per share LMAT The Nasdaq
Filing Documents
- lmat20240502_8k.htm (8-K) — 31KB
- ex_666356.htm (EX-99.1) — 353KB
- 0001437749-24-014372.txt ( ) — 531KB
- lmat-20240502.xsd (EX-101.SCH) — 3KB
- lmat-20240502_def.xml (EX-101.DEF) — 11KB
- lmat-20240502_lab.xml (EX-101.LAB) — 15KB
- lmat-20240502_pre.xml (EX-101.PRE) — 11KB
- lmat20240502_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 2, 2024, LeMaitre Vascular, Inc. (the "Company") issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Disclaimer on Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticip
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. The following exhibits are furnished or filed as part of this Report, as applicable: (d) Exhibits. Exhibit No. Description 99.1 Press release issued by LeMaitre Vascular, Inc. on May 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature(s) Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LeMaitre Vascular, Inc. Date: May 2, 2024 By: Joseph P. Pellegrino, Jr. /s/ JOSEPH P. PELLEGRINO, JR. Joseph P. Pellegrino, Jr. Chief Financial Officer Exhibit Index Exhibit No. Description 99.1 Press release issued by LeMaitre Vascular, Inc. on May 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)